TERT promoter mutations contribute to subset prognostication of lower-grade gliomas

TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas

(2013) Hideyuki Arita et al.   ACTA NEUROPATHOLOGICA

TERT promoter mutations in primary and secondary glioblastomas

(2013) Naosuke Nonoguchi et al.   ACTA NEUROPATHOLOGICA

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss

(2013) Hideyuki Arita et al.   ACTA NEUROPATHOLOGICA

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system

(2013) Christian Koelsche et al.   ACTA NEUROPATHOLOGICA

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma

(2013) Marc Remke et al.   ACTA NEUROPATHOLOGICA

Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study

(2013) Pedro Castelo-Branco et al.   LANCET ONCOLOGY

Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors

(2013) Aden Ka-Yin Chan et al.   MODERN PATHOLOGY

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TERT Promoter Mutations in Familial and Sporadic Melanoma

(2013) S. Horn et al.   SCIENCE

Highly Recurrent TERT Promoter Mutations in Human Melanoma

(2013) F. W. Huang et al.   SCIENCE

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology

(2010) David Capper et al.   ACTA NEUROPATHOLOGICA

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective

(2010) Martin J. van den Bent   ACTA NEUROPATHOLOGICA

Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

(2010) Philippe Metellus et al.   ACTA NEUROPATHOLOGICA

hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis

(2010) Jillian de Wilde et al.   BMC CANCER

Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis

(2009) Sandra Camelo-Piragua et al.   ACTA NEUROPATHOLOGICA

IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas

(2009) Takuya Watanabe et al.   AMERICAN JOURNAL OF PATHOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gliomas With 1p/19q Codeletion:a.k.a. Oligodendroglioma

(2008) Gregory Cairncross et al.   CANCER JOURNAL

Oligodendroglioma

(2008) Martin J. Van den Bent et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE